Literature DB >> 21252932

Clinical pharmacology for development of topical dermatological products: present and future opportunities for safety and efficacy.

S Cho1, E D Bashaw.   

Abstract

The development of topical products for dermatological diseases represents an untapped opportunity for the clinical pharmacologist. Assessment of bioavailability of topical drugs and its utility in weighing benefit vs. risk has been unique and challenging, compared with assessments for conventional systemic drugs. However, with continued advances in analytical methods and growing interests in discovering biomarkers, the future opportunities for clinical pharmacology to advance topical drug development processes are enormous and will be limited only by our drive and determination to push science forward.

Mesh:

Substances:

Year:  2011        PMID: 21252932     DOI: 10.1038/clpt.2010.283

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  1 in total

1.  The Relevance of Assessing Subjective Experiences of Skin Toxicity During Adjuvant Radiotherapy for Breast Cancer.

Authors:  Gioia Bottesi; Antonio Stefanelli; Giovanni Ambroso; Gianni Baratto; Eleonora Carraro; Agostino Cristaudo; Laura Giuntoli; Giada Maramaldi; Martino Meneghin; Genny Pozzati; Alessandra Semenzato; Stefano Togni; Giulio Vidotto
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.